Literature DB >> 18801884

Pharmacokinetics of sunitinib in hemodialysis.

H Izzedine, M C Etienne-Grimaldi, N Renée, S Vignot, G Milano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18801884     DOI： 10.1093/annonc/mdn626

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  14 in total

1.  Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience.

Authors:  Aditya V Shetty; Marc R Matrana; Bradley J Atkinson; Amber L Flaherty; Eric Jonasch; Nizar M Tannir
Journal:  Clin Genitourin Cancer       Date:  2014-01-18       Impact factor: 2.872

Review 2.  Practical guidelines for dose individualization of anticancer targeted drugs.

Authors:  María Isabel Sáez; Cristina Quero; José Manuel Trigo; Begoña Muros; Emilio Alba
Journal:  Clin Transl Oncol       Date:  2012-10-12       Impact factor: 3.405

Review 3.  Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).

Authors:  Laura Cosmai; Maurizio Gallieni; Wanda Liguigli; Camillo Porta
Journal:  J Nephrol       Date:  2016-05-06       Impact factor: 3.902

4.  Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.

Authors:  Paola Di Gion; Friederike Kanefendt; Andreas Lindauer; Matthias Scheffler; Oxana Doroshyenko; Uwe Fuhr; Jürgen Wolf; Ulrich Jaehde
Journal:  Clin Pharmacokinet       Date:  2011-09       Impact factor: 6.447

Review 5.  Renal effects of targeted anticancer therapies.

Authors:  Camillo Porta; Laura Cosmai; Maurizio Gallieni; Paolo Pedrazzoli; Fabio Malberti
Journal:  Nat Rev Nephrol       Date:  2015-03-03       Impact factor: 28.314

6.  Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)-Exploring Its Possible Clinical Relevance in Cancer Patients.

Authors:  Michal Rihacek; Iveta Selingerova; Ivo Kocak; Ilona Kocakova; Eva Rihackova; Dalibor Valik; Jaroslav Sterba
Journal:  Curr Oncol       Date:  2022-06-07       Impact factor: 3.109

Review 7.  Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations.

Authors:  Javier Puente; Xavier García Del Muro; Álvaro Pinto; Nuria Láinez; Emilio Esteban; José Ángel Arranz; Enrique Gallardo; María José Méndez; Pablo Maroto; Enrique Grande; Cristina Suárez
Journal:  Target Oncol       Date:  2016-04       Impact factor: 4.493

Review 8.  Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function.

Authors:  Łukasz Mielczarek; Anna Brodziak; Paweł Sobczuk; Maciej Kawecki; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Cancer Chemother Pharmacol       Date:  2021-03-25       Impact factor: 3.333

9.  Pharmacokinetic/Pharmacodynamic Analysis of a Hemodialyzed Patient Treated with 25 mg of Sunitinib.

Authors:  Satoshi Noda; Susumu Kageyama; Teruhiko Tsuru; Shigehisa Kubota; Tetsuya Yoshida; Keisei Okamoto; Yusaku Okada; Shin-Ya Morita; Tomohiro Terada
Journal:  Case Rep Oncol       Date:  2012-09-21

Review 10.  Treatment of patients with metastatic renal cell carcinoma undergoing hemodialysis: case report of two patients and short literature review.

Authors:  John Syrios; Georgios Kechagias; Nicolas Tsavaris
Journal:  BMC Nephrol       Date:  2013-04-12       Impact factor: 2.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.